Oxford Finance LLC
Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.
Business Model:
Revenue: $25M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Oxford Finance LLC Information
Geographic Data
Address: 115 South Union Street
City: Alexandria
State: VA
Zip: 22314
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$900M
Social
Linkedin
Crunchbase
Metrics
2,110,333Website Global Rank
9,425Website Monthly Traffic
Twitter Followers
Description
Oxford Finance LLC delivers flexible financial solutions to healthcare and life sciences companies worldwide. Our capital provides clients with the fuel needed for innovation and growth.
Contact Phone:
+17035194900
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2013 | Plus Therapeutics | Post-IPO Debt | 27M |
| 1/2019 | AliveCor | Debt Financing | 20M |
| 4/2015 | ReShape Lifesciences | Post-IPO Debt | 12M |
| 1/2014 | Proteus Digital Health | Debt Financing | 31.6M |
| 4/2014 | RF Surgical Systems | Venture Round | 15M |
| 1/2013 | Agile Therapeutics | Debt Financing | 15M |
| 11/2015 | Continuum Healthcare | Debt Financing | 13.9M |
| 9/2014 | Asensus Surgical | Post-IPO Debt | 25M |
| 8/2015 | Ocera Therapeutics | Post-IPO Debt | 20M |
| 7/2014 | Cerus | Post-IPO Debt | 30M |
| 9/2020 | Vedanta Biosciences | Debt Financing | 15M |
| 3/2011 | NeoVista | Debt Financing | 20M |
| 10/2019 | Equillium | Post-IPO Debt | 20M |
| 10/2013 | Monteris Medical | Debt Financing | 5M |
| 12/2020 | RxSight | Debt Financing | 60M |
| 9/2020 | Selecta Biosciences | Post-IPO Debt | 35M |
| 10/2012 | Entellus Medical | Debt Financing | 17M |
| 6/2022 | Antheia | Debt Financing | 0 |
| 7/2015 | AlterG | Debt Financing | 15M |
| 12/2013 | Apollo Endosurgery | Debt Financing | 50M |
| 8/2014 | diaDexus | Post-IPO Debt | 15M |
| 7/2010 | Tethys BioScience | Debt Financing | 10M |
| 11/2022 | Pearl Street | Debt Financing | 115M |
| 8/2013 | PrimeSource Healthcare Systems | Debt Financing | 5.5M |
| 11/2015 | Zyga Technology | Debt Financing | 15M |
| 6/2012 | Avanir Pharmaceuticals | Post-IPO Debt | 30M |
| 10/2013 | Monteris Medical | Venture Round | 0 |
| 10/2022 | ALX Oncology | Post-IPO Debt | 100M |
| 7/2021 | 4D Pharma | Post-IPO Debt | 29.9M |
| 1/2017 | Eiger BioPharmaceuticals | Post-IPO Debt | 25M |
| 2/2019 | Continuing Healthcare Solutions | Debt Financing | 43.3M |
| 3/2016 | Superior Biologics | Debt Financing | 50M |
| 4/2017 | Cerapedics | Debt Financing | 20M |
| 6/2019 | AcelRx Pharmaceuticals | Post-IPO Debt | 25M |
| 6/2016 | Regulus Therapeutics | Post-IPO Debt | 30M |
| 3/2019 | Evolus | Post-IPO Debt | 100M |
| 12/2013 | Amicus Therapeutics | Post-IPO Debt | 10M |
| 5/2017 | Castle Biosciences | Debt Financing | 20M |
| 4/2014 | Larimar Therapeutics | Debt Financing | 20M |
| 7/2010 | Zogenix | Debt Financing | 35M |
| 2/2020 | Syros Pharmaceuticals | Debt Financing | 60M |
| 12/2020 | Nature’s Fynd | Debt Financing | 45M |
| 1/2015 | Minerva Neuroscience | Post-IPO Debt | 15M |
| 1/2022 | Choice Health at Home | Debt Financing | 0 |
| 5/2013 | CardioFocus | Debt Financing | 11M |
| 11/2017 | Puma Biotechnology | Post-IPO Equity | 100M |
| 5/2016 | ADMA Biologics | Post-IPO Debt | 4M |
| 2/2012 | Horizon Pharma | Post-IPO Debt | 60M |
| 8/2017 | AirXpanders | Post-IPO Debt | 15M |
| 10/2020 | SpendMend | Debt Financing | 55M |
| 4/2015 | Celula | Debt Financing | 10M |
| 9/2013 | Singulex, Inc. | Debt Financing | 40M |
| 6/2015 | ADMA Biologics | Post-IPO Debt | 21M |
| 9/2019 | Codex DNA | Series A | 25M |
| 4/2007 | Argos Therapeutics | Debt Financing | 5M |
| 7/2016 | Senseonics | Post-IPO Debt | 30M |
| 11/2017 | VitalConnect | Debt Financing | 20M |
| 2/2022 | Centogene | Post-IPO Debt | 0 |
| 1/2017 | ConforMIS | Post-IPO Debt | 50M |
| 11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
| 5/2021 | Kala Pharmaceuticals | Post-IPO Debt | 125M |
| 2/2011 | Intuity Medical | Venture Round | 20M |
| 7/2021 | Impel NeuroPharma | Debt Financing | 50M |
| 3/2020 | Epic Healthcare Staffing | Debt Financing | 104.3M |
| 9/2020 | Enable Injections | Debt Financing | 25M |
| 4/2014 | Conventus Orthopaedics | Debt Financing | 10M |
| 8/2019 | MolecuLight | Debt Financing | 7.5M |
| 3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
| 12/2013 | CymaBay Therapeutics | Debt Financing | 5M |
| 4/2017 | Reata Pharmaceuticals | Post-IPO Debt | 35M |
| 9/2010 | SuperDimension | Debt | 15M |
| 6/2014 | Tobira Therapeutics | Debt Financing | 15M |
| 10/2022 | Verona Pharma | Post-IPO Debt | 150M |
| 10/2007 | Tengion | Series C | 33M |
| 3/2018 | Xeris Pharmaceuticals | Debt Financing | 45M |
| 3/2011 | AirXpanders | Series C | 3M |
| 5/2012 | Pacira Pharmaceuticals | Post-IPO Debt | 27.5M |
| 11/2021 | Platelet BioGenesis | Series B | 75.5M |
| 7/2014 | Cardiff Oncology | Post-IPO Debt | 15M |
| 9/2014 | Trevena | Post-IPO Debt | 35M |
| 1/2014 | Auspex Pharmaceuticals | Debt Financing | 15M |
| 8/2016 | CVRx | Debt Financing | 20M |
| 12/2015 | Aratana Therapeutics | Post-IPO Debt | 40M |
| 8/2014 | Tarsa Therapeutics | Debt Financing | 10M |
| 10/2009 | Zogenix | Series B | 36M |
| 9/2014 | Pulmonx | Debt Financing | 20M |
| 5/2014 | Ceterix Orthopaedics | Debt Financing | - |
| 5/2015 | Edgemont Pharmaceuticals | Debt Financing | 5M |
| 9/2020 | Collage Rehabilitation Partners | Debt Financing | - |
| 9/2019 | Xeris Pharmaceuticals | Post-IPO Debt | 85M |
| 9/2012 | CareDx | Debt Financing | 15M |
| 5/2022 | Silk Road Medical | Post-IPO Debt | 250M |
| 10/2019 | LogicBio Therapeutics | Post-IPO Debt | 20M |
| 4/2019 | Summit Healthcare REIT | Debt Financing | 96M |
| 1/2017 | Oxford BioTherapeutics | Debt Financing | 10M |
| 8/2016 | Bi02 Medical | Debt Financing | 3M |
| 2/2012 | Ceptaris Therapeutics | Debt Financing | 15M |
| 8/2014 | HTG Molecular Diagnostics | Debt Financing | 16M |
| 8/2011 | Keystone Dental | Debt Financing | 20M |
| 1/2015 | InterValve | Debt Financing | 3M |
| 12/2016 | Strongbridge Biopharma | Post-IPO Debt | 40M |
| 8/2019 | ObsEva | Post-IPO Debt | 75M |
| 6/2014 | Intellicyt | Debt Financing | 4M |
| 1/2016 | Omeros | Post-IPO Debt | 70M |
| 3/2014 | Omeros | Post-IPO Debt | 32M |
| 5/2016 | Omeros | Post-IPO Debt | 20M |
| 11/2022 | Renibus Therapeutics | Debt Financing | 10M |
| 9/2007 | CASI Pharmaceuticals | Post-IPO Debt | 20M |
| 11/2015 | Venus Concept | Debt Financing | 20M |
| 1/2021 | Immunocore | Debt Financing | 100M |
| 6/2016 | Monteris Medical | Debt Financing | 10M |
| 6/2014 | Durect | Post-IPO Equity | 20M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 5/2015 | Labcyte | Debt Financing | 17M |
| 4/2021 | Mainstay Medical | Debt | 50M |
| 2/2020 | Genapsys | Debt Financing | 75M |
| 4/2015 | Inhibrx | Debt Financing | 20M |
| 1/2016 | Bi02 Medical | Debt Financing | 5M |
| 7/2013 | Continuum Healthcare | Debt Financing | 11.5M |
| 4/2012 | NanoString Technologies | Debt Financing | 15M |
| 11/2018 | Nevakar | Debt Financing | 30M |
| 7/2012 | LENSAR, Inc. | Debt Financing | 10M |
| 4/2018 | Cardiac Dimensions | Series B | 39M |
| 4/2014 | Senseonics | Debt Financing | 10M |
| 1/2014 | Halozyme Therapeutics | Post-IPO Debt | 20M |
| 12/2013 | Halozyme Therapeutics | Post-IPO Debt | 30M |
| 3/2011 | SynergEyes | Venture Round | 5M |
| 12/2020 | Greenbrook TMS | Post-IPO Debt | 30M |
| 11/2021 | Kezar Life Sciences | Post-IPO Debt | 50M |
| 6/2022 | SeLux Diagnostics | Debt Financing | 0 |
| 11/2007 | BioVex | Series E | 35M |
| 2/2009 | Pearl Therapeutics | Debt Financing | 8M |
| 12/2013 | Acura Pharmaceuticals | Post-IPO Debt | 10M |
| 6/2014 | Relypsa | Post-IPO Debt | 35M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 12/2015 | MDRejuvena | Debt Financing | 3M |
| 1/2022 | Sierra Oncology | Post-IPO Debt | 125M |
| 11/2011 | Avantis Medical Systems | Debt Financing | 3M |
| 6/2016 | Ignyta | Post-IPO Debt | 42M |
| 5/2019 | RefleXion Medical | Debt Financing | 60M |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 11/2018 | Karius | Debt Financing | 25M |
| 7/2018 | QuVa Pharma | Debt Financing | 41M |
| 4/2016 | Nuvectra | Debt Financing | 45M |
| 3/2014 | Navidea Biopharmaceuticals | Post-IPO Debt | 30M |
| 11/2014 | Lexicon Pharmaceuticals | Equity | 150M |
| 6/2022 | Antheia | Debt Financing | 0 |
| 6/2022 | SeLux Diagnostics | Debt Financing | 0 |
| 5/2022 | Silk Road Medical | Post-IPO Debt | 0 |
| 3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
| 3/2022 | Lexicon Pharmaceuticals | Post-IPO Debt | 0 |
| 2/2022 | Centogene | Post-IPO Debt | 0 |
| 1/2022 | Sierra Oncology | Post-IPO Debt | 0 |
| 1/2022 | Choice Health at Home | Debt Financing | 0 |
| 11/2021 | Kezar Life Sciences | Post-IPO Debt | 0 |
| 11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
